Gui-E Lai1, Jian Zhou2, Cui-Liu Huang1, Cun-Jun Mai1, Yi-Mei Lai1, Zhi-Qin Lin1, Tao Peng1, Yuan Luo3, Feng-En Liu1. 1. Department of Vascular and Breast Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, China. 2. Department of Neurosurgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China. 3. Department of Medical Ultrasonics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Abstract
Background: DNA methylation status is strongly associated with the prognosis of breast invasive carcinoma (BRCA). Elucidating the mechanisms underlying DNA methylation coupled with determining its biological function is imperative to the effective development of treatment and prevention strategies for breast cancer. Methods: We retrieved transcriptome and DNA methylation profiles of BRCA patients from The Cancer Genome Atlas (TCGA) database, then applied the "limma" package in R software to identify differentially expressed genes (DEGs) and aberrantly methylated genes. Next, we used the "MethylMix" package to screen for methylation-driven genes, and performed univariate and multivariate Cox regression analyses to determine the prognostic value of the methylation-driven genes and clinical characteristics. We validated these findings in 51 breast cancer tissues alongside 51 corresponding normal tissues. Furthermore, we used cell experiments to clarify the biological function and underlying molecular mechanisms of HOTAIRM1 in vitro. Results: A total of 25 methylation-driven genes were identified in the dataset. Results from univariate and multivariate Cox regression showed that SYN2, HOTAIRM1, BCAS1, and ALDOC were significantly associated with patient prognosis. Immunohistochemistry and quantitative real-time polymerase chain reaction (qRT-PCR) results showed that the expression levels of SYN2 and HOTAIRM1 were negatively correlated with BRCA stage, whereas those of BCAS1 and ALDOC were positively correlated with BRCA stage. Results from in vitro experiments showed that knockdown HOTAIRM1 expression promoted breast cancer cells proliferation, clone formation, and invasion. Up-regulation of HOTAIRM1 inhibited breast cancer cells proliferation, clone formation, and invasion. Conclusions: In summary, low HOTAIRM1 expression is a significant prognostic factor for the survival of BRCA patients and thus could be a potential therapeutic target for the treatment of BRCA. 2022 Gland Surgery. All rights reserved.
Background: DNA methylation status is strongly associated with the prognosis of breast invasive carcinoma (BRCA). Elucidating the mechanisms underlying DNA methylation coupled with determining its biological function is imperative to the effective development of treatment and prevention strategies for breast cancer. Methods: We retrieved transcriptome and DNA methylation profiles of BRCA patients from The Cancer Genome Atlas (TCGA) database, then applied the "limma" package in R software to identify differentially expressed genes (DEGs) and aberrantly methylated genes. Next, we used the "MethylMix" package to screen for methylation-driven genes, and performed univariate and multivariate Cox regression analyses to determine the prognostic value of the methylation-driven genes and clinical characteristics. We validated these findings in 51 breast cancer tissues alongside 51 corresponding normal tissues. Furthermore, we used cell experiments to clarify the biological function and underlying molecular mechanisms of HOTAIRM1 in vitro. Results: A total of 25 methylation-driven genes were identified in the dataset. Results from univariate and multivariate Cox regression showed that SYN2, HOTAIRM1, BCAS1, and ALDOC were significantly associated with patient prognosis. Immunohistochemistry and quantitative real-time polymerase chain reaction (qRT-PCR) results showed that the expression levels of SYN2 and HOTAIRM1 were negatively correlated with BRCA stage, whereas those of BCAS1 and ALDOC were positively correlated with BRCA stage. Results from in vitro experiments showed that knockdown HOTAIRM1 expression promoted breast cancer cells proliferation, clone formation, and invasion. Up-regulation of HOTAIRM1 inhibited breast cancer cells proliferation, clone formation, and invasion. Conclusions: In summary, low HOTAIRM1 expression is a significant prognostic factor for the survival of BRCA patients and thus could be a potential therapeutic target for the treatment of BRCA. 2022 Gland Surgery. All rights reserved.
Entities:
Keywords:
Breast invasive carcinoma (BRCA); DNA methylation; long noncoding RNA HOTAIRM1 (lncRNA HOTAIRM1); metastasis; proliferation
Authors: Balázs Győrffy; Giulia Bottai; Thomas Fleischer; Gyöngyi Munkácsy; Jan Budczies; Laura Paladini; Anne-Lise Børresen-Dale; Vessela N Kristensen; Libero Santarpia Journal: Int J Cancer Date: 2015-07-30 Impact factor: 7.396
Authors: Merry Jennifer Markham; Kerri Wachter; Neeraj Agarwal; Monica M Bertagnolli; Susan Marina Chang; William Dale; Catherine S M Diefenbach; Carlos Rodriguez-Galindo; Daniel J George; Timothy D Gilligan; R Donald Harvey; Melissa L Johnson; Randall J Kimple; Miriam A Knoll; Noelle LoConte; Robert G Maki; Jane Lowe Meisel; Jeffrey A Meyerhardt; Nathan A Pennell; Gabrielle B Rocque; Michael S Sabel; Richard L Schilsky; Bryan James Schneider; William D Tap; Robert G Uzzo; Shannon Neville Westin Journal: J Clin Oncol Date: 2020-02-04 Impact factor: 44.544
Authors: Whitney L Do; Jazib Gohar; Lauren E McCullough; Karla I Galaviz; Karen N Conneely; K M Venkat Narayan Journal: Obes Rev Date: 2021-07-18 Impact factor: 9.213
Authors: Thomas P Ahern; Anne Broe; Timothy L Lash; Deirdre P Cronin-Fenton; Sinna Pilgaard Ulrichsen; Peer M Christiansen; Bernard F Cole; Rulla M Tamimi; Henrik Toft Sørensen; Per Damkier Journal: J Clin Oncol Date: 2019-04-17 Impact factor: 44.544
Authors: Gurdeep S Mannu; Zhe Wang; John Broggio; Jackie Charman; Shan Cheung; Olive Kearins; David Dodwell; Sarah C Darby Journal: BMJ Date: 2020-05-27
Authors: Jack Cuzick; Ivana Sestak; John F Forbes; Mitch Dowsett; Simon Cawthorn; Robert E Mansel; Sibylle Loibl; Bernardo Bonanni; D Gareth Evans; Anthony Howell Journal: Lancet Date: 2019-12-12 Impact factor: 79.321